Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases

Официальное название

Biocollection for the Study of Genetic and Immunological Abnormalities in Rare Pediatric-onset Autoimmune and Auto Inflammatory Diseases

Обзор

Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges. This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.

Подробное описание

A disease is said to be "rare" when it affects one person in 2,000, which represents three million people in France. Most rare diseases (80%) are genetic in origin ; the earlier they start in childhood, the more severe they can be. Rare pediatric diseases include autoimmune diseases (systemic lupus, juvenile dermatomyositis and juvenile idiopathic arthritis) and autoimmune diseases (interferonopathies, FMF, CAPS, TRAPS, and DADA2). Systemic autoimmune diseases are characterized by an inappropriate adaptive immune response (mediated by autoreactive T and/or B lymphocytes) with the production of autoantibodies directed against the constituents of the self (tolerance breakdown). Autoinflammatory diseases, unlike autoimmune diseases, correspond to an excess in the innate immune response (cytokines, macrophages, NK cells, granulocytes, etc.)..The precise pathophysiological mechanisms of these diseases have yet to be fully elucidated. Recent research has led to advances in the diagnosis and identification of monogenic forms of these diseases, particularly in early onset, familial, and syndromic forms. Nevertheless, the rarity of these diseases and limited availability of biological samples are major challenges that need to be overcome.

Thus, the aims of this study were as follows:

\- The creation of a biological collection: primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, which, through various research projects, will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases.

Вмешательства

• Генная терапия Blood sample for genetic analysis
  genetic analysis (WES, WGS) for the identification of germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood
• Другое Blood sample for immunological response assessments
  Identifying specific immunological factors in patients with rare pediatric autoimmune and auto inflammatory diseases
• Другое Blood sample to identify relevant biomarker of the disease
  Research biomarkers for diagnosis, prognosis and monitoring of disease activity

Первичные конечные точки

• To Identify germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood [Срок оценки: Baseline]

Вторичные конечные точки (6)

• Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [Срок оценки: Baseline]
• Levels of anti-double stranded DNA [Срок оценки: Baseline]
• Levels of complement components C3 and C4 [Срок оценки: Baseline]
• Level of IFN Signature score [Срок оценки: Baseline]
• Concentration of circulating IFN-alpha [Срок оценки: Baseline]
• Presence or absence of anti-type I interferons autoantibodies [Срок оценки: Baseline]

Критерии участия

Критерии включения

• Patients
• minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years), or syndromic or familial
• relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years of age) or syndromic or familial,
• weight greater than 5 kg
• Patient/parents/guardians who were informed of the study and signed the consent form.
• patient affiliated to a social security scheme

Healthy volunteer participants

• minor or adult participants with no age restrictions
• weight over 5 kg
• Subject /Parents/guardians who were informed of the study and signed a consent form.
• Patient affiliated to a social security scheme

Критерии исключения

Patients

\- Subjects /Parents/guardians, refusing to participate in the study

Healthy volunteer participants :

• active infection (viral, bacterial, parasitic)
• history of neoplasia (< 5 years) or current neoplasia
• participants with a personal or family history of autoimmune disease
• immunocompromised participant (immune deficiency or transplant recipient)
• Subjects/parents/guardians refusing to participate in the study
• Adults under legal protection (guardianship, curatorship)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Другое

Центры проведения

Франция · 13 центров

• Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant — Bron
• Hôpital Jeanne de Flandre (CHU de Lille) — Lille
• Hôpital Claude Huriez (CHU de Lille) — Lille
• Hôpital Archet 2 — Nice
• Hôpital Necker-Enfants Malades (AP-HP) — Paris
• Hôpital Robert Debré (AP-HP) — Paris
• Hôpital Kremlin-Bicêtre (AP-HP) — Paris
• Hôpital Nord (CHU ST-Etienne) — Saint-Etienne
• … и ещё 5 центров

Идентификаторы

NCT: NCT06435468 · 69HCL23_1252

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗